



#6

OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/932,172A

DATE: 05/29/2002

TIME: 16:24:14

Input Set : A:\STEM1110-3.ST25.txt

Output Set: N:\CRF3\05292002\I932172A.raw

ENTERED

2 <110> APPLICANT: STEM CELL PHARMACEUTICALS, INC.
3 TWARDZIK, Daniel R.
4 PERNET, Andre
5 FELKER, Thomas S.
6 PASKELL, Stefan
8 <120> TITLE OF INVENTION: TGF-alpha POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF
USE THEREFOR
10 <130> FILE REFERENCE: STEM1110-3
12 <140> CURRENT APPLICATION NUMBER: US 09/932,172A
13 <141> CURRENT FILING DATE: 2001-08-17
15 <150> PRIOR APPLICATION NUMBER: US 09/641,587
16 <151> PRIOR FILING DATE: 2000-08-17
18 <150> PRIOR APPLICATION NUMBER: US 09/492,935
19 <151> PRIOR FILING DATE: 2000-01-27
21 <150> PRIOR APPLICATION NUMBER: US 09/378,567
22 <151> PRIOR FILING DATE: 1999-08-19
24 <160> NUMBER OF SEQ ID NOS: 7
26 <170> SOFTWARE: PatentIn version 3.0
28 <210> SEQ ID NO: 1
29 <211> LENGTH: 50
30 <212> TYPE: PRT
31 <213> ORGANISM: Homo sapiens
33 <400> SEQUENCE: 1
35 Val Val Ser His Phe Asn Asp Cys Pro Asp Ser His Thr Gln Phe Cys
36 1 5 10 15
38 Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Asp Lys Pro Ala Cys
39 20 25 30
41 Val Cys His Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu
42 35 40 45
44 Leu Ala
45 50
47 <210> SEQ ID NO: 2
48 <211> LENGTH: 50
49 <212> TYPE: PRT
50 <213> ORGANISM: Rattus norvegicus
52 <400> SEQUENCE: 2
54 Val Val Ser His Phe Asn Lys Cys Pro Asp Ser His Thr Gln Tyr Cys
55 1 5 10 15
57 Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Glu Lys Pro Ala Cys
58 20 25 30
60 Val Cys His Ser Gly Tyr Val Gly Val Arg Cys Glu His Ala Asp Leu
61 35 40 45
63 Asp Ala
64 50

RAW SEQUENCE LISTING

DATE: 05/29/2002

PATENT APPLICATION: US/09/932,172A

TIME: 16:24:14

Input Set : A:\STEM1110-3.ST25.txt


Output Set: N:\CRF3\05292002\I932172A.raw

66 <210> SEQ ID NO: 3
 67 <211> LENGTH: 57
 68 <212> TYPE: PRT
 69 <213> ORGANISM: Artificial sequence
 71 <220> FEATURE:
 72 <223> OTHER INFORMATION: Modified human TGF-alpha sequence
 74 <400> SEQUENCE: 3
 76 Ser Leu Ser Leu Pro Ala Met Val Val Ser His Phe Asn Asp Cys Pro
 77 1 5 10 15
 79 Asp Ser His Thr Gln Phe Cys Phe His Gly Thr Cys Arg Phe Leu Val
 80 20 25 30
 82 Gln Glu Asp Lys Pro Ala Cys Val Cys His Ser Gly Tyr Val Gly Ala
 83 35 40 45
 85 Arg Cys Glu His Ala Asp Leu Leu Ala
 86 50 55
 88 <210> SEQ ID NO: 4
 89 <211> LENGTH: 11
 90 <212> TYPE: PRT
 91 <213> ORGANISM: Artificial sequence
 93 <220> FEATURE:
 94 <223> OTHER INFORMATION: Modified human TGF-alpha sequence fragment
 96 <220> FEATURE:
 97 <221> NAME/KEY: VARIANT
 98 <222> LOCATION: (1)..(10)
 99 <223> OTHER INFORMATION: Xaa at residue 1, 5, 7 to 9 is independently V, G or A; Xaa

at

100 residue 6 is Y or F; and Xaa at residue 10 is R or K

102 <400> SEQUENCE: 4


 104 Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys

105 1 5 10

107 <210> SEQ ID NO: 5

108 <211> LENGTH: 7

109 <212> TYPE: PRT

110 <213> ORGANISM: Artificial sequence

112 <220> FEATURE:

113 <223> OTHER INFORMATION: Modified human TGF-alpha sequence fragment

115 <220> FEATURE:


116 <221> NAME/KEY: VARIANT

117 <222> LOCATION: (1)..(7)

 118 <223> OTHER INFORMATION: Xaa at residue 1 and 4 is E or D; Xaa at residue 3 and 7 is
 V, G,

119 or A; Xaa at residue 5 is L or I; and Xaa at residue 6 is D or E

122 <400> SEQUENCE: 5


 124 Xaa His Xaa Xaa Xaa Xaa Xaa

125 1 5

127 <210> SEQ ID NO: 6

128 <211> LENGTH: 18

129 <212> TYPE: PRT

130 <213> ORGANISM: Artificial sequence

132 <220> FEATURE:

133 <223> OTHER INFORMATION: Modified human TGF-alpha sequence fragment

RAW SEQUENCE LISTING

DATE: 05/29/2002

PATENT APPLICATION: US/09/932,172A

TIME: 16:24:14

Input Set : A:\STEM1110-3.ST25.txt

Output Set: N:\CRF3\05292002\I932172A.raw

135 <220> FEATURE:
 136 <221> NAME/KEY: VARIANT
 137 <222> LOCATION: (1)..(18)
 138 <223> OTHER INFORMATION: Xaa at residue 1, 5, 7-9, 14, 18 is indep. V, G, or A; Xaa
 at
 139 residue 6 is Y or F; Xaa at residue 10 is R or K; Xaa at residue 12,
 140 15 is indep. E or D; Xaa at residue 16 is L or I; Xaa at residue
 141 17 is D or E
 143 <400> SEQUENCE: 6
 W--> 145 Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa His Xaa Xaa Xaa
 W--> 146 1 5 10 15
 W--> 148 Xaa Xaa
 151 <210> SEQ ID NO: 7
 152 <211> LENGTH: 7
 153 <212> TYPE: PRT
 154 <213> ORGANISM: Artificial sequence
 156 <220> FEATURE:
 157 <223> OTHER INFORMATION: Modified human TGF-alpha sequence fragment
 159 <220> FEATURE:
 160 <221> NAME/KEY: VARIANT
 161 <222> LOCATION: (1)..(7)
 162 <223> OTHER INFORMATION: Xaa at residue 1 and 2 is indep. V, G, and A; Xaa at residue
 7 is
 163 K or D
 165 <400> SEQUENCE: 7
 W--> 167 Xaa Xaa Ser His Phe Asn Xaa
 168 1 5

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/932,172A

DATE: 05/29/2002
TIME: 16:24:15

Input Set : A:\STEM1110-3.ST25.txt
Output Set: N:\CRF3\05292002\I932172A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:4; Xaa Pos. 1, 5, 6, 7, 8, 9, 10
Seq#:5; Xaa Pos. 1, 3, 4, 5, 6, 7
Seq#:6; Xaa Pos. 1, 5, 6, 7, 8, 9, 10, 12, 14, 15, 16, 17, 18
Seq#:7; Xaa Pos. 1, 2, 7

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 8